Genus (GNS) Earns “Hold” Rating from Liberum Capital
Other research analysts have also recently issued reports about the stock. N+1 Singer raised shares of Genus to a buy rating and lifted their price target for the company from GBX 1,844 ($25.01) to GBX 2,485 ($33.70) in a research report on Monday, October 30th. Peel Hunt reissued a buy rating and set a GBX 2,600 ($35.26) price target on shares of Genus in a research report on Monday, October 9th. Finally, Kepler Capital Markets reissued a hold rating and set a GBX 2,353 ($31.91) price target on shares of Genus in a research report on Wednesday, November 15th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Genus presently has an average rating of Hold and a consensus target price of GBX 2,270.60 ($30.79).
Genus (GNS) opened at GBX 2,540 ($34.45) on Monday. Genus has a 12-month low of GBX 1,652 ($22.40) and a 12-month high of GBX 2,597 ($35.22). The stock has a market cap of $1,550.00 and a PE ratio of 4,792.45.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/18/genus-gns-earns-hold-rating-from-liberum-capital.html.
Genus Company Profile
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company’s segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe.
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.